MMP9 and urinary bladder carcinoma: These results indicate that proTAME-containing therapies significantly inhibit MMP2 and MMP9 expression, particularly in RT4 bladder cancer cells, suggesting its potential to selectively modulate key pathways involved in tumor invasion and metastasis.